Home > Insider Trading > Filing (0001192482-13-000246)

Filing Details

Accession Number:: 0001192482-13-000246
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-12-19 14:29:23
Reporting Period:: 2013-12-17

Filing Date:: 2013-12-19
Accepted Time:: 2013-12-19 14:29:23
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1361248	Tetralogic Pharmaceuticals Corp	TLOG	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1553355	N. James Woody	C/O Tetralogic Pharmaceuticals Corp 343 Phoenixville Pike Malvern PA 19355		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-12-17	243,189	$7.00	243,189	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2013-12-17	12,159	$7.00	255,348	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2013-12-17	6,079	$7.00	261,427	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2013-12-17	354,663	$0.00	616,090	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2013-12-17	17,733	$0.00	633,823	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2013-12-17	8,866	$0.00	642,689	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2013-12-17	227,266	$0.00	869,955	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2013-12-17	11,363	$0.00	881,318	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2013-12-17	5,681	$0.00	886,999	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2013-12-17	104,118	$7.00	991,117	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2013-12-17	5,205	$7.00	996,322	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2013-12-17	2,602	$7.00	998,924	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2013-12-17	2,850	$6.40	1,001,774	No	4	X	Indirect	See footnotes
Common Stock	Acquisiton	2013-12-17	143	$6.40	1,001,917	No	4	X	Indirect	See footnotes
Common Stock	Acquisiton	2013-12-17	71	$6.40	1,001,988	No	4	X	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	X	Indirect	See footnotes
No	4	X	Indirect	See footnotes
No	4	X	Indirect	See footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Convertible Preferred Stock	Disposition	2013-12-17	354,663	$0.00	354,663	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2013-12-17	17,733	$0.00	17,733	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2013-12-17	8,866	$0.00	8,866	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2013-12-17	227,266	$0.00	227,266	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2013-12-17	11,363	$0.00	11,363	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2013-12-17	5,681	$0.00	5,681	$0.00
Common Stock	Convertible Notes	Disposition	2013-12-17	104,118	$0.00	104,118	$7.00
Common Stock	Convertible Notes	Disposition	2013-12-17	5,205	$0.00	5,205	$7.00
Common Stock	Convertible Notes	Disposition	2013-12-17	2,602	$0.00	2,602	$7.00
Common Stock	Series C Warrants	Disposition	2013-12-17	2,850	$0.00	2,850	$6.40
Common Stock	Series C Warrants	Disposition	2013-12-17	143	$0.00	143	$6.40
Common Stock	Series C Warrants	Disposition	2013-12-17	71	$0.00	71	$6.40

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	X	Indirect
No	4	X	Indirect
No	4	X	Indirect

Footnotes

Directly owned by LVP Life Science Ventures, III, L.P.
Directly owned by LVP III Associates, L.P.
Directly owned by LVP III Partners, L.P.
Shares of Series B Convertible Preferred Stock were automatically converted to the same number of shares of Common Stock at the time of the Company's initial public offering on December 17, 2013.
Shares of Series C Convertible Preferred Stock were automatically converted to the same number of shares of Common Stock at the time of the Company's initial public offering which occurred on December 17, 2013.
The Convertible Notes and Accrued Interest automatically converted into Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering, at the initial public offering price of $7.00 per share, which occurred on December 17, 2013.
The warrants were automatically exercised immediately prior to the closing of the Issuer's initial public offering for a number of shares of common stock equal to the warrant amount divided by $6.4022 and net exercised at the initial public offering price of $7.00 per share.
The reported securities are owned directly by each of LVP Life Science Ventures III, L.P. ("LVP III"), LVP III Associates, L.P. ("Associates"), and LVP III Partners, L.P. ("Partners"). LVP GP III, LLC ("GP III") is the general partner of LVP III, Associates, and Partners. The reporting person, a member of GP III, shares voting and investment power with respect to these shares but disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein